ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1585013
This article is part of the Research TopicNovel Molecular Targets in Cancer TherapyView all 35 articles
Outcomes and prognostic factors of alternative treatment regimens for angioimmunoblastic T-cell lymphoma: a retrospective analysis
Provisionally accepted
- 1Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- 2Department of Otolaryngology, the third affiliated hospital of Zhengzhou University, Zhengzhou, China
- 3Henan Provincial People's Hospital, Zhengzhou, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Angioimmunoblastic T-cell lymphoma (AITL), representing the second most prevalent subtype of peripheral T-cell lymphoma, currently lacks standardized frontline therapeutic strategies.In this study, we evaluated the survival outcomes and prognostic factors in 154 patients with AITL treated with one of four regimens: CHOP (cyclophosphamide, vincristine, epirubicin, prednisone), CHOPE (CHOP + etoposide), CPET (chidamide, prednisone, etoposide, thalidomide), or GDPT (gemcitabine, cisplatin, dexamethasone, thalidomide). Among them, 144 patients had complete survival follow-up data.Survival differences across groups were analyzed using the log-rank test, while variations in clinical parameters were assessed via chi-square tests and one-way ANOVA. Univariate and multivariate Cox regression analyses were conducted to identify factors associated with progression-free survival (PFS) and overall survival (OS).The 5-year OS and PFS rates for the entire cohort were 36.6% (95% CI: 0.275-0.488) and 32.2% (95% CI: 0.233-0.451), respectively. Patients who were younger (<60 or <70 years), had Ann Arbor stage I/II disease, or exhibited lower Eastern Cooperative Oncology Group (ECOG) performance status scores demonstrated significantly improved OS and PFS following treatment. Notably, among patients with ECOG <2, those treated with the CPET regimen achieved longer PFS and OS compared to those receiving CHOP or CHOPE. In contrast, for patients with ECOG ≥2, no significant survival differences were observed across treatment regimens. Both univariate and multivariate analyses identified ECOG performance status as an independent prognostic factor for survival outcomes.For patients with a low ECOG performance status, the CPET regimen may offer promising survival outcomes.
Keywords: Angioimmunoblastic T cell lymphoma, response rate, Progression-free survival, overall survival, Prognostic factor
Received: 28 Feb 2025; Accepted: 27 May 2025.
Copyright: © 2025 Yan, Wang, Zhang, Zhang, Zhang, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mingzhi Zhang, Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Zunmin Zhu, Henan Provincial People's Hospital, Zhengzhou, 450000, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.